Company news
Sunshine Biopharma Inc. news in 2025
Sunshine Biopharma Inc.'s news releases, calls and decks from 2025, newest first.
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
October 28, 2025
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
October 28, 2025
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
October 20, 2025
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
October 16, 2025
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
October 14, 2025
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
October 9, 2025
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
July 2, 2025
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
June 11, 2025
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
May 15, 2025
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
May 6, 2025
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
April 21, 2025
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
April 3, 2025
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
April 2, 2025
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
April 2, 2025
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
April 1, 2025
Sunshine Biopharma expands presence in the $53.9 billion global antibiotics market with the acquisition of marketing rights for two new antibiotics in Canada
March 25, 2025
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
March 24, 2025
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
March 10, 2025
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
January 20, 2025
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
January 14, 2025